ClinicalTrials.gg
Not yet recruitingNCT07706829AI-PRAUpdated Oct 2, 2026

Artificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) Study

An observational study in Parkinson Disease (PD), REM Sleep Behavior Disorder (iRBD) and Neurogenic Orthostatic Hypotension, sponsored by Queen Mary University of London. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Queen Mary University of London · Observational

How we know

Updated Oct 2, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 428 studies in Parkinson Disease with a site in France — 63 open to participants now, 76 under way, 4 of them phase 3. Parkinson Disease · France.

Planned enrollment
66th of 98
60 · median 90
Started
2026
with 14 others
Observational
99 of 428
22 open now
Primary completion
2027-09
later than 47 of 75 live
Registered
423rd of 428
by date

Among the 428 studies in Parkinson Disease with a site in France, this one is the 66th largest by planned enrollment of the 98 observational ones that give a count, is one of 15 that started in 2026, is one of 99 observational ones, reaches primary completion later than 47 of the 75 other live ones, and was the 423rd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

63 of the 428 studies in Parkinson Disease with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 428 studies in Parkinson Disease with a site in France, or all of them as a file.
02

Study summary

The study aims to provide initial proof-of-concept validation data of an artificial intelligence-based model to estimate individual Parkinson's disease risk using demographic, clinical, genetic information and digital biomarker data collected via a smartwatch and a mobile application.

Read the detailed description

Background: Everyday electronic devices may detect subtle motor and non-motor abnormalities years before the clinical diagnosis of Parkinson's disease (PD) providing opportunities for early detection.

Study aim and impact: This study aims to validate an artificial intelligence based model that provides an individualised risk of PD based on demographic, clinical, genetic and digital biomarker data (smartwatch and a phone app). An early diagnosis will allow timely interventions to manage symptoms and risk stratification of participants for early clinical trials.

Methods: 60 people at risk of PD (either with polysomnography confirmed REM sleep behaviour disorder; OR neurogenic orthostatic hypotension; OR objective hyposmia on smell test) will be recruited.

Participants will complete study assessments to provide PD risk estimation using current research clinical criteria and the artificial intelligence model. Study assessments will include:

  • In-person visits (baseline and 6 months) to complete validated questionnaires and a neurological examination (including cognitive and motor assessments).
  • Brain dopamine (DAT) scan (baseline only).
  • blood tests for PD polygenic risk score (baseline only) and plasma urate (in males only at baseline and 6 months).
  • Smartwatch and phone app: a smartwatch linked to the participants' smartphone will provide digital biomarker and additional clinical information through questionnaires via study phone app.

An artificial intelligence based model (AI-PROGNOSIS model) will use these digital data in combination with demographics, clinical and genetic information to provide an individualised PD risk estimation.

Accuracy measures of the risk estimates from the current research diagnostic criteria and artificial intelligence model using the presence of abnormal dopamine DAT scan as the ground truth for PD diagnosis will be provided.

03

Conditions studied

  • Parkinson Disease (PD)
  • REM Sleep Behavior Disorder (iRBD)
  • Neurogenic Orthostatic Hypotension
  • Hyposmia

Keywords

  • prodromal Parkinson's disease
  • neurogenic orthostatic hypotension
  • REM sleep behaviour disorder
  • hyposmia
  • Digital biomarkers
  • AI-PROGNOSIS
  • Smartwatch
  • Wearable electronic devices
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People at risk of PD due to the presence of clinical markers associated with prodromal PD including one of the following:

  1. REM sleep behaviour disorder (RBD) confirmed with polysomnography.
  2. Neurogenic orthostatic hypotension (nOH) defined as a drop in systolic / diastolic blood pressure ≥ 20/10mmHg within 3 minutes of active standing or tilt-table test, and with a blunted heart rate response (ΔHeart rate/ΔSBP ratio \< 0.5 bpm/mmHg).
  3. Objective hyposmia defined as University of Pennsylvania Smell Identification Test (UPSIT) score ≤ 15th percentile for age and sex.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 50 years.
  2. At least one of the following clinical markers for PD risk:

    1. REM sleep behaviour disorder (RBD) confirmed with polysomnography.
    2. Neurogenic orthostatic hypotension (nOH) defined as a drop in systolic / diastolic blood pressure ≥ 20/10mmHg within 3 minutes of active standing or tilt-table test, and with a blunted heart rate response (ΔHeart rate/ΔSBP ratio \< 0.5 bpm/mmHg).
    3. Objective hyposmia defined as University of Pennsylvania Smell Identification Test (UPSIT) score ≤ 15th percentile for age and sex.
  3. Able and willing to give informed written consent.
  4. Use of compatible smartphone (mobile operating system Android version 11 or newer). A smartwatch will be provided to each participant for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Clinical diagnosis of Parkinson's disease (PD) according to MDS clinical diagnostic criteria.
  2. Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or another PD medication, except for low-dose treatment of restless leg syndrome (with permission of investigator).
  3. Dementia defined as deterioration of cognitive function severe enough to impair functioning on daily activities.
  4. Active treatment with neuroleptics, reserpine or metoclopramide (these drugs should be discontinued for at least 6 months before screening visit) due to their interference with dopamine transporter SPECT imaging acquisition and interpretation.
  5. Pregnant women.
  6. Concomitant participation in interventional studies.
  7. Unwilling or unable to give informed written consent.
  8. Vulnerable individuals as defined by the HRA.
  9. Inability to use the smartwatch and/or the mAI-Health app for the purpose of the study as judged by the investigator.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort of people at risk of Parkinson's disease

    People at risk of PD defined by the presence of either polysomnography-confirmed REM sleep behaviour disorder, neurogenic orthostatic hypotension or objective hyposmia documented with smell test.

    Device: Smartwatch and phone app

Interventions

  • DeviceSmartwatch and phone app

    Wearing a smartwatch and using a mobile phone application for 6 months in order to provide digital biomarker data and additional self reported clinical information.

06

What researchers measure

Primary outcomes

  1. Classification performance of the PD risk artificial intelligence-based model

    Classification performance of the model in predicting dopaminergic degeneration defined as a binary outcome: a participant will be considered to have dopaminergic degeneration if putamen specific binding ratio (SBR) on the most affected side is below 2 standard deviations of age-matched normative data or shows abnormal visual inspection by a qualified nuclear medicine specialist on dopamine transporter SPECT imaging.

    Time frame: From enrolment to 6 months

Secondary outcomes

  1. Usability of study digital environment (mAI-Health phone app)

    System Usability Scale (SUS) scores. The SUS includes 10 statement items regarding the usability of the study phone application that will be rated on a scale of 1 - 5 (strongly disagree - strongly agree). Range 10-50 with higher scores meaning a better outcome.

    Time frame: At 6 month visit

07

Study locations

3 sites
08

References and documents

Publications

  • Hastings A, Cullinane P, Wrigley S, Revesz T, Morris HR, Dickson JC, Jaunmuktane Z, Warner TT, De Pablo-Fernandez E. Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism. Neurology. 2024 Jun 11;102(11):e209453. doi: 10.1212/WNL.0000000000209453. Epub 2024 May 17. PubMed 38759132 ↗
  • Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB; MDS Task Force on the Definition of Parkinson's Disease. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2019 Oct;34(10):1464-1470. doi: 10.1002/mds.27802. Epub 2019 Aug 14. PubMed 31412427 ↗
  • Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015 Oct;30(12):1600-11. doi: 10.1002/mds.26431. PubMed 26474317 ↗

Individual participant data

Plan to share: Yes — After completion of the study and publication of results, study data for participants that specifically consented for this, will be made accessible in a public repository, after full anonymisation, to the research community following FAIR principles for non-commercial research purposes

Supporting information: Study protocol

Time frame: To be determined (after completion of the study and publication of the main study results).

Access criteria: Qualified investigators will be able to access fully anonymised dataset according to ethical permissions through public repository.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 11 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 16, 2026
StartEst.
Oct 1, 2026was Jul 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2026→Oct 1, 2026
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Start date Jul 1, 2026→Oct 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07706829
Collaborators
Hospital Ruber Internacional, University Hospital, Toulouse, Aristotle University Of Thessaloniki
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Eduardo de Pablo Fernández
Contact
e.depablofernandez@qmul.ac.uk
+44 20 7882 8693

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion